Chemotherapy and chemo-resistance in nasopharyngeal carcinoma

Guan, Shuzhen; Ji, Wei; Huang, Lingkun; Wu, Li

doi:10.1016/j.ejmech.2020.112758

Cited by 95 publications

(55 citation statements)

References 167 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The EBV miRNAs are mainly BamHI-A region rightward transcripts (BARTs) and BamHI fragment H rightward open reading frame 1 (BHRF1) miRNA clusters [64,65]. In the latent 1-2 types, miRNAs encoded by BART are detectable, whereas miRNAs from BHRF1 are mainly detectable in latent type 3 and lytic infected cells [66]. EBV genes have been reported to be involved in NPC malignant progression, including EMT, cellular motility, angiogenesis [67], metastasis [68], and treatment resistance [66].…”

Section: Epstein-barr Virus (Ebv) Infection and Npc Metastasismentioning

confidence: 99%

Metastasis of nasopharyngeal carcinoma: What we know and do not know

et al. 2021

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) has the highest metastatic rate among head and neck cancers, with its underlying mechanism not yet fully unveiled. High- versus low-metastasis, NPC cell lines have been established. The footpad-popliteal lymph node metastasis model and other in vivo models have been stably used to study NPC metastasis. The histological appearance and the expression of epithelial-to-mesenchymal transition (EMT) markers might be helpful in selecting high-risk NPC patients for developing post-treatment metastasis. Tested EMT markers and their protein expression levels that correlate with patient disease-free survival in large patient cohorts include E-cadherin, N-cadherin, CD44, Twist, Snail, and Cyclin D1. Epstein-Barr virus (EBV) infection can trigger NPC metastasis from multiple angles via multiple signaling pathways. High endothelial venules are commonly seen in NPC tissues, with their role in NPC metastasis requiring clarification. The molecules that promote and inhibit NPC metastasis are introduced, with a focus on cytokines SPINK6, serglycin, interleukin 8 (IL8), Wnt family member 5A (WNT5A), and chemokine C-C motif ligand 2 (CCL2). Two videos showing NPC cells with and without SPINK6 knocked down are presented. Future directions for studying NPC metastasis are also discussed.

show abstract

Section: Epstein-barr Virus (Ebv) Infection and Npc Metastasismentioning

confidence: 99%

Metastasis of nasopharyngeal carcinoma: What we know and do not know

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Modern considerations have shown that ncRNAs, particularly miRNAs and lncRNAs, may play an imperative role in NPC resistance by mediating efflux, death escape, upgrading DNA repair, EMT, CSC, EBV, exosomes, and apoptosis. 5 In addition, ncRNAs can modulate the function of targets of drug action and regulate genes related to drug metabolism and transport. 70 In addition, inactivation of oncogenic miRNAs promoted the expression of target tumour suppressor genes, while activation of tumour suppressor miRNAs suppressed the expression of oncogenes, which may be related to the recovery of drug sensitivity.…”

Section: Non-coding Rnas Involved In Drug Resistance Of Npcmentioning

confidence: 99%

“… 3 One of the main problems in the treatment of patients with nasopharyngeal carcinoma is the resistance of cancer cells to radiotherapy and chemotherapy, which tends to lead to unsatisfactory treatment results, tumour recurrence and poor prognosis. 2 , 4 , 5 Hence, the main objective of current clinical research is to implement appropriate strategies through which patients can overcome resistance during chemotherapy or radiotherapy.…”

Section: Introductionmentioning

confidence: 99%

Involvement of Non-Coding RNAs in Chemo- and Radioresistance of Nasopharyngeal Carcinoma

Xiao

2021

CMAR

View full text Add to dashboard Cite

“…[4][5][6] Currently, radiotherapy and chemotherapy are standard treatments for NPC. [7][8][9][10] The prognosis of NPC is determined by the disease stage. 11 Patients with early-stage NPC have a 5-year survival rate of approximately 90%, while those at an advanced stage have a 5-year survival rate of less than 50%.…”

Section: Introductionmentioning

confidence: 99%

Performance of Plasma HSP90α, Serum EBV VCA IgA Antibody and Plasma EBV DNA for the Diagnosis and Prognosis Prediction of Nasopharyngeal Carcinoma

Qian¹,

Guo²,

Chen³

et al. 2021

CMAR

View full text Add to dashboard Cite

The aim of this study was to evaluate the effectiveness of Epstein-Barr virus (EBV) VCA-IgA antibody, EBV DNA and HSP90α alone or in combinations for the diagnosis and prognostic prediction of nasopharyngeal carcinoma (NPC). Methods: A total of 113 treatment-naïve patients with NPC and 40 healthy controls were enrolled. Plasma HSP90α and serum EBV VCA IgA antibody were detected using ELISA, and plasma EBV DNA was quantified using qPCR assay. The effectiveness of plasma HSP90α level, serum EBV VCA IgA antibody and plasma EBV DNA was examined in the diagnosis and prognosis prediction of NPC. Results: Higher plasma HSP90α, serum EBV VCA IgA antibody and plasma viral load of EBV DNA were detected in NPC patients than in healthy controls (P < 0.001). The plasma HSP90α levels, serum EBV VCA IgA antibody titers and plasma viral load of EBV DNA were significantly greater in NPC patients with stages III and IV than in those with stages I and II (P < 0.001), and significantly lower plasma HSP90α levels, serum EBV VCA IgA antibody titers and plasma viral load of EBV DNA were found in the good prognosis group than in the poor prognosis group post-treatment (P < 0.05). The area under representative operating curves (AUCs) of plasma HSP90α, serum EBV VCA IgA antibody and plasma EBV DNA alone and in combination were 0.884, 0.841, 0.934 and 0.954 for the diagnosis of NPC, respectively. Univariate and multivariate Cox proportional hazards regression analyses identified HSP90α as an independent prognostic factor for NPC. Conclusion:The combination of plasma HSP90α, serum EBV VCA IgA antibody and plasma EBV DNA shows high diagnostic performance for NPC, and plasma HSP90α may be a potential marker for diagnosis and prognosis prediction of NPC.

show abstract

Chemotherapy and chemo-resistance in nasopharyngeal carcinoma

Cited by 95 publications

References 167 publications

Metastasis of nasopharyngeal carcinoma: What we know and do not know

Metastasis of nasopharyngeal carcinoma: What we know and do not know

Involvement of Non-Coding RNAs in Chemo- and Radioresistance of Nasopharyngeal Carcinoma

Performance of Plasma HSP90α, Serum EBV VCA IgA Antibody and Plasma EBV DNA for the Diagnosis and Prognosis Prediction of Nasopharyngeal Carcinoma

Contact Info

Product

Resources

About